486 related articles for article (PubMed ID: 30274981)
1. The Role of Angiogenesis in Hepatocellular Carcinoma.
Morse MA; Sun W; Kim R; He AR; Abada PB; Mynderse M; Finn RS
Clin Cancer Res; 2019 Feb; 25(3):912-920. PubMed ID: 30274981
[TBL] [Abstract][Full Text] [Related]
2. Effect of novel anti-tumor and anti-angiogenesis drug taurolactone on angiogenic factor AGGF1 and angiogenesis mimicry in patients with hepatocellular carcinoma.
Liu S; Wei Y; Nie L; Tang Z; Lu Q; Liang Q
BMC Cancer; 2024 May; 24(1):614. PubMed ID: 38773427
[TBL] [Abstract][Full Text] [Related]
3. Emerging therapies targeting growth factors in hepatocellular carcinoma.
Ruff SM; Pawlik TM
Expert Opin Pharmacother; 2024 Feb; 25(3):255-262. PubMed ID: 38591252
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma, vascular endothelial growth factor receptors-targeting agents, and hypertension: A much more complicated relationship than expected.
Porta C; Negri F; Cosmai L
Cancer; 2024 Apr; 130(8):1208-1209. PubMed ID: 38280211
[No Abstract] [Full Text] [Related]
5. Molecular approaches to treatment of hepatocellular carcinoma.
Lachenmayer A; Alsinet C; Chang CY; Llovet JM
Dig Liver Dis; 2010 Jul; 42 Suppl 3(0 3):S264-72. PubMed ID: 20547313
[TBL] [Abstract][Full Text] [Related]
6. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Xu DZ; Hernandez S; Liu J; Huang C; Mulla S; Wang Y; Lim HY; Zhu AX; Cheng AL;
N Engl J Med; 2020 May; 382(20):1894-1905. PubMed ID: 32402160
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions.
Hilmi M; Neuzillet C; Calderaro J; Lafdil F; Pawlotsky JM; Rousseau B
J Immunother Cancer; 2019 Nov; 7(1):333. PubMed ID: 31783782
[TBL] [Abstract][Full Text] [Related]
8. Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.
Greten TF; Lai CW; Li G; Staveley-O'Carroll KF
Gastroenterology; 2019 Jan; 156(2):510-524. PubMed ID: 30287171
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular Carcinoma.
Villanueva A
N Engl J Med; 2019 Apr; 380(15):1450-1462. PubMed ID: 30970190
[No Abstract] [Full Text] [Related]
10. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
Finn RS; Ryoo BY; Merle P; Kudo M; Bouattour M; Lim HY; Breder V; Edeline J; Chao Y; Ogasawara S; Yau T; Garrido M; Chan SL; Knox J; Daniele B; Ebbinghaus SW; Chen E; Siegel AB; Zhu AX; Cheng AL;
J Clin Oncol; 2020 Jan; 38(3):193-202. PubMed ID: 31790344
[TBL] [Abstract][Full Text] [Related]
11. New Systemic Treatments in Advanced Hepatocellular Carcinoma.
Sanduzzi-Zamparelli M; Díaz-Gonzalez Á; Reig M
Liver Transpl; 2019 Feb; 25(2):311-322. PubMed ID: 30317696
[TBL] [Abstract][Full Text] [Related]
12. Association Between Aspirin Use and Risk of Hepatocellular Carcinoma.
Simon TG; Ma Y; Ludvigsson JF; Chong DQ; Giovannucci EL; Fuchs CS; Meyerhardt JA; Corey KE; Chung RT; Zhang X; Chan AT
JAMA Oncol; 2018 Dec; 4(12):1683-1690. PubMed ID: 30286235
[TBL] [Abstract][Full Text] [Related]
13. Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma.
Dimri M; Satyanarayana A
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32093152
[TBL] [Abstract][Full Text] [Related]
14. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
Bangaru S; Marrero JA; Singal AG
Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
[TBL] [Abstract][Full Text] [Related]
15. Tumour evolution in hepatocellular carcinoma.
Craig AJ; von Felden J; Garcia-Lezana T; Sarcognato S; Villanueva A
Nat Rev Gastroenterol Hepatol; 2020 Mar; 17(3):139-152. PubMed ID: 31792430
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
17. VEGF in Signaling and Disease: Beyond Discovery and Development.
Apte RS; Chen DS; Ferrara N
Cell; 2019 Mar; 176(6):1248-1264. PubMed ID: 30849371
[TBL] [Abstract][Full Text] [Related]
18. A global view of hepatocellular carcinoma: trends, risk, prevention and management.
Yang JD; Hainaut P; Gores GJ; Amadou A; Plymoth A; Roberts LR
Nat Rev Gastroenterol Hepatol; 2019 Oct; 16(10):589-604. PubMed ID: 31439937
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma.
Llovet JM; Kelley RK; Villanueva A; Singal AG; Pikarsky E; Roayaie S; Lencioni R; Koike K; Zucman-Rossi J; Finn RS
Nat Rev Dis Primers; 2021 Jan; 7(1):6. PubMed ID: 33479224
[TBL] [Abstract][Full Text] [Related]
20. Metabolic rearrangements in primary liver cancers: cause and consequences.
Satriano L; Lewinska M; Rodrigues PM; Banales JM; Andersen JB
Nat Rev Gastroenterol Hepatol; 2019 Dec; 16(12):748-766. PubMed ID: 31666728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
